Merck & Co and SR One were among the investors in a series C round for the small molecule drug developer led by Pivotal BioVenture Partners.

US-based small molecule drug developer HotSpot Therapeutics completed a $100m series C round on Monday led by Pivotal BioVenture Partners, a life sciences investment vehicle owned by property developer Nan Fung.

The round included pharmaceutical firm Merck & Co’s MRL Ventures Fund and SR One Capital Management, the investment firm spun off by pharmaceutical firm GlaxoSmithKline, as well as B Capital Group, the investment partner of consulting firm Boston Consulting Group.

Caas Capital Management, Revelation Partners, Pavilion Capital, Monashee Investment…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn